With 0.56 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.36 million shares. During the session, the Banks – Regional company that operates in wider Financial sector, reached to the highest price of $72.7548 whereas the lowest price it dropped to was $67.67. The 52-week range on BMA shows that it touched its highest point at $118.42 and its lowest point at $40.94 during that stretch. It currently has a 1-year price target of $116.07. With its current market cap of 4.41 billion, BMA has annualized dividend of $0.00 while the current yield stands at 0.00%. BMA paid its most recent dividend on 1723766400, while the ex-dividend date for that was 1723766400. Beta for the stock currently stands at 1.65.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BMA was up-trending over the past week, with a rise of 1.67%, but this was down by -17.10% over a month. Three-month performance dropped to -10.42% while six-month performance fell -29.82%. The stock lost -27.44% in the past year, while it has gained 31.36% so far this year. A look at the trailing 12-month EPS for BMA yields 0.07 with Next year EPS estimates of 12.06. For the next quarter, that number is 1.92. This implies an EPS growth rate of 67.40% for this year and 50.93% for next year. EPS is expected to grow by 41.65% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -15.97%.
Float and Shares Shorts:
At present, 62.82 million BMA shares are outstanding with a float of 62.74 million shares on hand for trading. On 2025-06-13, short shares totaled 0.22 million, which was 34.0 higher than short shares on 1747267200. In addition to Mr. Juan Martin Parma as the firm’s Chief Executive Officer, Mr. Jorge Francisco Scarinci C.F.A. serves as its CFO, Finance Manager & IR Manager.
Institutional Ownership:
Through their ownership of 0.11229999 of BMA’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BMA since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BMA analysts setting a high price target of 152.78587 and a low target of 83.071075, the average target price over the next 12 months is 109.96068. Based on these targets, BMA could surge 117.61% to reach the target high and rise by 18.32% to reach the target low. Reaching the average price target will result in a growth of 56.62% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $4975.58574 being high and $4437.38207 being low. For BMA, this leads to a yearly average estimate of $4730.91669. Based on analyst estimates, the high estimate for the next quarter is $3478.27 and the low estimate is $3478.27. The average estimate for the next quarter is thus $3478.27.
